Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR
Date: 2021-06-02 Authors: Bissonnette R, Gottlieb AB, Langley RG, Leonardi CL, Papp KA, Pariser DM, Uy J, Lafferty KP, Langholff W, Fakharzadeh S, Berlin JA, Brouwer ES, Greenspan AJ, Strober BE. Category: Psoriasis Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials
Date: 2021-06-01 Authors: Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, Reich K. Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Measuring Atopic Dermatitis Disease Severity: The Potential for Electronic Tools to Benefit Clinical Care
Date: 2021-04-09 Authors: Maintz L, Bieber T, Bissonnette R, Jack C. Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response
Date: 2021-04-18 Authors: Villani AP, Pavel AB, Wu J, Fernandes M, Maari C, Saint-Cyr Proulx E, Jack C, Glickman J, SeulahChoi, He H, Ungar B, Estrada Y, Kameyama N, Zhang N, Gonzales J, Tardif JC, Krueger JG, Bissonnette R, Guttman-Yassky E. Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list […]
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent
Date: 2021-04-08 Authors: Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A Category: Psoriasis Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
Date: 2021-04-01 Authors: Simpson EL, Wollenberg A, Bissonnette R, Silverberg JI, Papacharalambous J, Zhu L, Zhang W, Beebe JS, Vincent M, Peeva E, Bushmakin AG, Cappelleri JC, Chen L, Sikirica V, Xenakis J Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). […]
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.
Date: 2021-03-04 Authors: Mrowietz U, Burden AD, Pinter A, Reich K, SchÀkel K, Baum P, Datsenko Y, Deng H, Padula SJ, Thoma C, Bissonnette R Category: Psoriasis Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
The preponderance of evidence supports an AhR-dependent mechanism of action of tapinarof.
Date: 2021-03-04 Authors: Bissonnette R, Gold LS, Rubenstein DS, Tallman AM, Armstrong A Category: Dermatitis (all types), Psoriasis Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Folliculitis with tapinarof, when it occurs, is generally mild, self-limiting, and rarely interferes with therapy.
Date: 2021-03-01 Authors: Bissonnette R, Gold LS, Rubenstein DS, Tallman AM, Armstrong A Category: Dermatitis (all types), Psoriasis Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).
Date: 2021-02-15 Authors: Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, Guttman-Yassky E, Marnell D, Bissonnette R, Waibel J, Nunes FP, DeLozier AM, Angle R, Gamalo M, Holzwarth K, Goldblum O, Zhong J, Janes J, Papp K Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list […]
